Arabic Arabic English English French French German German
dark

Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced the completion of patient enrolment into the phase 3 ERADICATE study. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nearly 48,000 boosters given yesterday; 14 community cases; 34 people in hospital; two in ICU

Next Post

Ketamine and psychological therapy helped severe alcoholics abstain for longer in trial

Related Posts
Total
0
Share